HIMS241220C32500
- 0.01
- -0.04-80.00%
Hims & Hers Health Newsroom
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Issues a Hold Rating on Hims & Hers Health (HIMS)
Unusual Options Activity: HIMS, FN and Others Attract Market Bets, HIMS V/OI Ratio Reaches 115.4
Hims & Hers Health: Sell Rating Due to Compounding Exemption Risks and Uncertain GLP-1 Contributions
Sector Update: Health Care Stocks Mixed Premarket Friday
Daily short sale tracking: Micron Technology's short volume increased by 4 million, with a short sale ratio of 11%
Hims & Hers Health Shares Fall on FDA Declaration of End to Tirzepatide Shortage
Top Gap Ups and Downs on Thursday: ACN, MU, VRTX and More
Hims & Hers Health Options Spot-On: On December 19th, 150.18K Contracts Were Traded, With 641.97K Open Interest
Unusual Options Activity: SNAP, WMT and Others Attract Market Bets, SNAP V/OI Ratio Reaches 1136.4
FDA Says Eli Lilly's Zepbound Shortage Over, but Gives Compounders Grace Period
Hims & Hers Health Off 11% On FDA Decision
The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com
Express News | FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection
Express News | FDA Issued A New Decision Determining The Tirzepatide Injection Shortage Is Resolved
10 Health Care Stocks With Whale Alerts In Today's Session
Hims & Hers Health Insider Sold Shares Worth $6,244,284, According to a Recent SEC Filing
Hims & Hers Health Options Trading: A Deep Dive Into Market Sentiment
Health-care Sector Faces Mixed Prospects in 2025, Morgan Stanley Says